Skip to main content

Table 4 Association between POAF and underlying medical conditions on admission

From: A double-blind randomised controlled trial on the effect of Tocovid, a tocotrienol-rich capsule on postoperative atrial fibrillation at the National Heart Institute, Kuala Lumpur: an interim blinded analysis

Medical condition Total*, n (%) Non-POAF group, n (%) POAF group, n (%) χ2 p value
COPD
 Yes 2 (1.7) 2 (100) 0 (0) 1.00a
 No 114 (98.3) 79 (69.3) 35 (30.7)   
Asthma
 Yes 1 (0.9) 1 (100) 0 (0) 1.00a
 No 115 (99.1) 80 (69.6) 35 (30.4)   
Hypertension
 Yes 96 (82.8) 67 (69.8) 29 (30.2) 0.000 0.97
 No 20 (17.2) 14 (70.0) 6 (30.0)   
Diabetes mellitus
 Yes 82 (70.1) 59 (72) 23 (28) 0.952 0.33
 No 35 (29.9) 22 (62.9) 13 (37.1)   
Hypercholesterolemia
 Yes 97 (85.1) 69 (71.1) 28 (28.90) 1.030 0.31
 No 17 (14.9) 10 (58.8) 7 (41.2)   
Chronic kidney disease
 Yes 15 (13.0) 10 (66.7) 5 (33.33) 0.77a
 No 100 (87.0) 70 (70.0) 30 (30.0)   
Current or ex-smoker
 Yes 63 (58.9) 41 (65.1) 22 (34.9) 6.074 0.014*
 No 44 (41.1) 38 (86.4) 6 (13.6)   
Alcohol intake
 Yes 6 (6.1) 3 (50) 3 (50) 0.173a
 No 93 (93.9) 70 (75.3) 23 (24.)   
  1. Total n varies slightly for each item due to a small amount of missing data in each
  2. COPD chronic obstructive pulmonary disease
  3. aTest using Fisher Exact Test
  4. *p value significant at p < 0.05 using Chi-Square test